Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.

about

The making of bispecific antibodies Bufalin induced apoptosis in SCC‑4 human tongue cancer cells by decreasing Bcl‑2 and increasing Bax expression via the mitochondria‑dependent pathway.Death Receptors: New Opportunities in Cancer Therapy.

P2860

Q42323236-04279824-3673-4C71-B527-3E95091161AC Q46293367-E0537A03-9F35-400B-BDBE-94E7429C98C9 Q47108799-E414D9EE-C40D-4C8B-8AA3-E98AB67FD7D3

P2860

Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.

Item

http://www.wikidata.org/entity/Q38823727

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Dual Agonist Surrobody Simulta ...... 5 to Induce Cancer Cell Death.

@en

type

Item

label

Dual Agonist Surrobody Simulta ...... 5 to Induce Cancer Cell Death.

@en

prefLabel

Dual Agonist Surrobody Simulta ...... 5 to Induce Cancer Cell Death.

@en

P1476

Dual Agonist Surrobody Simulta ...... R5 to Induce Cancer Cell Death

@en

P2093

Aaron L Kurtzman

http://www.w3.org/2001/XMLSchema#string

Alexsandr Faynboym

http://www.w3.org/2001/XMLSchema#string

Arun K Kashyap

http://www.w3.org/2001/XMLSchema#string

Carina Wimer

http://www.w3.org/2001/XMLSchema#string

Charles H Hannum

http://www.w3.org/2001/XMLSchema#string

John C Reed

http://www.w3.org/2001/XMLSchema#string

Lawrence Horowitz

http://www.w3.org/2001/XMLSchema#string

Li Xu

http://www.w3.org/2001/XMLSchema#string

Michael Horowitz

http://www.w3.org/2001/XMLSchema#string

Paul W Diaz

http://www.w3.org/2001/XMLSchema#string

P2860

Genome engineering using the CRISPR-Cas9 system

Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway

Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5

cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination

Combinatorial surrobody libraries.

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.

Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)

P304

114-124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-15-0400

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Teruki Yanagi

P577

2015-10-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26516157

http://www.w3.org/2001/XMLSchema#string

P932

4707094

http://www.w3.org/2001/XMLSchema#string

Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.

about

P2860

P2860

Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932